Literature DB >> 2311636

Factors affecting survival in primary superficial bladder cancer.

J Flamm1, L Havelec.   

Abstract

In a retrospective study of 345 patients with primary superficial transitional cell carcinoma of the bladder, factors present at the time of initial evaluation and which affect survival were identified. All patients were treated initially by transurethral resection with separate resection of the tumor base and margin. 89 patients received no further treatment after resection of the tumor, 256 patients received adjuvant topical instillation therapy over a period of 6 weeks. The distribution of risk factors in both groups was comparable; the survival rate after 5 years showed no significant difference. The tumor-related mortality rate was 12.5%. The Cox regression model showed carcinoma in situ in the tumor margin and the absence of a tumor-associated tissue inflammatory reaction to be the most important risk factors. Beside these associated risk factors, poor differentiation of the tumor parameter was the most important prognostic factor.

Entities:  

Mesh:

Year:  1990        PMID: 2311636     DOI: 10.1159/000464017

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

1.  Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Authors:  Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

2.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

3.  Morphological predictors of survival in early and advanced gastric carcinoma.

Authors:  P Schmitz-Moormann; P Hermanek; G W Himmelmann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  Update on the management of non-muscle invasive bladder cancer.

Authors:  Saad Aldousari; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2010-02       Impact factor: 1.862

5.  Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.

Authors:  G Sauter; G Deng; H Moch; R Kerschmann; K Matsumura; S De Vries; T George; J Fuentes; P Carroll; M J Mihatsch
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

6.  Recurrence of superficial bladder tumours after transurethral resection.

Authors:  H Fuse; T Sakai; H Kimura; T Katayama
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

7.  p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer.

Authors:  H Moch; G Sauter; D Moore; M J Mihatsch; F Gudat; F Waldman
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Authors:  Erik Pasin; David Y Josephson; Anirban P Mitra; Richard J Cote; John P Stein
Journal:  Rev Urol       Date:  2008

9.  Selection of patients for intravesical therapy for superficial bladder cancer.

Authors:  Y Bedük; L S Yaman; S Baltaci; Y Z Müftüoğlu; T Yurdakul; O Göğüş
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

10.  The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group.

Authors:  L A Kiemeney; J A Witjes; A L Verbeek; R P Heijbroek; F M Debruyne
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.